JPH04104795A - Novel substance sbs and production thereof - Google Patents
Novel substance sbs and production thereofInfo
- Publication number
- JPH04104795A JPH04104795A JP21810490A JP21810490A JPH04104795A JP H04104795 A JPH04104795 A JP H04104795A JP 21810490 A JP21810490 A JP 21810490A JP 21810490 A JP21810490 A JP 21810490A JP H04104795 A JPH04104795 A JP H04104795A
- Authority
- JP
- Japan
- Prior art keywords
- reaction
- sbs
- methanol
- substance sbs
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims description 36
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000004042 decolorization Methods 0.000 claims abstract description 4
- 238000000921 elemental analysis Methods 0.000 claims abstract description 4
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 claims abstract description 4
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 4
- 239000011630 iodine Substances 0.000 claims abstract description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims abstract description 4
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000012286 potassium permanganate Substances 0.000 claims abstract description 4
- 238000000862 absorption spectrum Methods 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000003217 anti-cancerogenic effect Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 239000003005 anticarcinogenic agent Substances 0.000 abstract description 2
- 238000009630 liquid culture Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
- 241000218554 Lyophyllum Species 0.000 abstract 2
- 238000004040 coloring Methods 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 9
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000000717 tumor promoter Substances 0.000 description 3
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 240000006499 Flammulina velutipes Species 0.000 description 2
- 235000016640 Flammulina velutipes Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 235000001715 Lentinula edodes Nutrition 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000103635 Lyophyllum ulmarium Species 0.000 description 1
- 235000015934 Lyophyllum ulmarium Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PEYTUVXFLCCGCC-UHFFFAOYSA-N Teleocidin B4 Natural products C1C(CO)NC(=O)C(C(C)C)N(C)C2=CC(C(CCC3(C)C=C)(C)C(C)C)=C3C3=C2C1=CN3 PEYTUVXFLCCGCC-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000002897 organic nitrogen compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- PEYTUVXFLCCGCC-YGHSORLUSA-N teleocidin b Chemical compound C1[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)C2=CC([C@@](CC[C@]3(C)C=C)(C)C(C)C)=C3C3=C2C1=CN3 PEYTUVXFLCCGCC-YGHSORLUSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、血小板凝集抑制作用及び抗発ガンプロモータ
ー作用を有する新規物質SBS及びその製造方法に関す
る。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a novel substance SBS having platelet aggregation inhibitory activity and anti-cancer promoter activity, and a method for producing the same.
近年、担子菌類からの生理活性物質検索が盛んであり、
様々な報告がなされている。例えば、カワラタケやスエ
ヒロタケから抗腫瘍性物質が、マンネンタケから血圧降
下物質が見出され、その他にも種々の担子菌類より免疫
賦活物質、抗アレルギー物質、抗潰瘍物質等が見出され
ている。また、一般に常食されているきのこからも薬理
作用が見出されており、シイタケやエノキタケより抗腫
瘍性物質が、ヒラタケより血圧降下作用(特開平2−7
2121号公報)が知られている。また、文部省の特定
研究「食品機能の系統的解析と展開」を切掛けとして食
品の3次機能をうたった機能性食品が現在注目されてあ
り、日常摂取している食品の生体調節機能の研究及び食
品中の生理活性物質の検索も盛んに行われている。In recent years, there has been an active search for physiologically active substances from Basidiomycetes.
Various reports have been made. For example, anti-tumor substances have been found in Corsiella versicolor and Swahirotake mushrooms, antihypertensive substances have been found in Cypress mushrooms, and immunostimulating substances, anti-allergic substances, anti-ulcer substances, etc. have also been found in various Basidiomycetes. In addition, pharmacological effects have been found in commonly eaten mushrooms, with antitumor substances found in shiitake and enokitake, and blood pressure lowering effects in oyster mushrooms (Japanese Unexamined Patent Publication No. 2-7).
No. 2121) is known. In addition, functional foods that promote the tertiary functions of foods are currently attracting attention, with the Ministry of Education's specific research "Systematic analysis and development of food functions" as an opportunity, and research on the bioregulatory functions of foods we ingest on a daily basis. Searches for physiologically active substances in foods are also actively conducted.
本発明の目的は、シイタケ、エノキタケと並び食品きの
ことして常食されているリオフイラム ウルマリウムの
産生ずる新規生理活性物質及びその製造方法を提供する
ことにある。An object of the present invention is to provide a novel physiologically active substance produced by Liophyllum ulmarium, which is commonly eaten as a food mushroom along with shiitake and enokitake mushrooms, and a method for producing the same.
本発明を概説すれば、本発明の第1の発明は新規物質S
BSに関し、下記の理化学的物質を有することを特徴と
する。To summarize the present invention, the first invention of the present invention is a novel substance S
Regarding BS, it is characterized by having the following physical and chemical substances.
元素分析:C73,06% H11,85%分子量:
738(FAB−マススペクトルによる)
分子式: C,5H8,0゜
紫外部吸収スペクトル(メタノール中):第1図に示す
ように208nmに極大
吸収を示す。Elemental analysis: C73,06% H11,85% Molecular weight:
738 (according to FAB-mass spectrum) Molecular formula: C,5H8,0° ultraviolet absorption spectrum (in methanol): As shown in Figure 1, it exhibits maximum absorption at 208 nm.
赤外部吸収スペクトル(KBr錠):第2図に示すよう
に3400.2990.
2960.2920.1380.
1180.945 C[l+−’に吸収を示す。Infrared absorption spectrum (KBr tablet): 3400.2990. as shown in Figure 2. 2960.2920.1380. Absorption is shown at 1180.945 C[l+-'.
呈色反応:ニンヒドリン反応陰性、フェノール硫酸反応
陰性、ヨウ素反応陽性、
過マンガン酸カリウム脱色反応陽性
また、本発明の第2の発明は、新規物質SBSの製造方
法に関し、リオフイラム属に属する新規物質SBS生産
菌の培養物又は該生産菌の子実体より、第1の発明の新
規物質SBSを採取することを特徴とする。Color reaction: Negative ninhydrin reaction, negative phenol sulfuric acid reaction, positive iodine reaction, positive potassium permanganate decolorization reaction The second invention of the present invention relates to a method for producing a new substance SBS, which is a new substance SBS belonging to the genus Liophyllum. It is characterized in that the novel substance SBS of the first invention is collected from the culture of the producing bacteria or the fruiting bodies of the producing bacteria.
本発明の1例を示すと、新規物質SBS生産菌の子実体
としては、商品名「やまびこはんしめじ■」として大量
に人工栽培・市販されているものが利用できる。また菌
株の培養物の例としては、リオフイラム ウルマリウム
Lui8(FERM BP−1416)の培養物が利
用でき、本菌株の微生物学的性質は、特開昭63−27
3467号公報に記載されているが、本発明に使用され
る新規物質SBS生産菌は上記菌株に限らず、リオフイ
ラム属に属する菌株であればどのような菌株でも用いる
ことができる。To give an example of the present invention, as the fruiting body of the new substance SBS-producing bacterium, one that is artificially cultivated and commercially available in large quantities under the trade name "Yamabikohan Shimeji ■" can be used. As an example of a culture of a bacterial strain, a culture of Liophyllum ulmarium Lui8 (FERM BP-1416) can be used, and the microbiological properties of this strain are described in Japanese Patent Application Laid-open No. 63-27.
Although described in Japanese Patent No. 3467, the novel substance SBS-producing bacteria used in the present invention is not limited to the above-mentioned strains, but any strain belonging to the genus Liophyllum can be used.
新規物質SBSの製造方法は、子実体又は培養菌体の取
得、抽出、精製の3工程からなる。The method for producing the new substance SBS consists of three steps: obtaining fruiting bodies or cultured bacterial cells, extraction, and purification.
子実体は市販品が容易に入手可能であり、培養菌体は、
−船釣な液体培養法により得られる。The fruiting bodies are easily available commercially, and the cultured bacterial bodies are
- Obtained by liquid culture method.
例えば、炭素源としてグルコース、スクロース、デンプ
ン、デキストリン、グリセリン、油脂類など資化しつる
有機炭素類が、窒素源として酵母エキス、ペプトン、コ
ーンスチーブリカー脱脂大豆、大豆皮、肉エキス、アミ
ノ酸、アンモニウム塩などの有機窒素化合物や無機窒素
化合物が利用できる。そのほかに、マグネシウム塩、リ
ン酸塩、カリウム塩等の無機塩類を加えてもよい。培養
温度は、15〜30℃が適当であり、20〜25℃が好
ましい。培養pHは、5〜9が適当であり、7〜8付近
が好ましい。培養は、振とう培養、静置培養どちらでも
よく、5〜15日で菌体が得られるが、静置培養のほう
がSBSの生産量は高い。次に抽出は、メタノール、エ
タノール、アセトン、酢酸エチル、クロロホルム等の有
機溶媒を用いて行われる。For example, assimilated organic carbons such as glucose, sucrose, starch, dextrin, glycerin, and fats and oils are used as carbon sources, and yeast extract, peptone, corn stew liquor as nitrogen sources, defatted soybeans, soybean hulls, meat extracts, amino acids, and ammonium salts are used as nitrogen sources. Organic nitrogen compounds and inorganic nitrogen compounds such as can be used. In addition, inorganic salts such as magnesium salts, phosphates, and potassium salts may be added. The culture temperature is suitably 15-30°C, preferably 20-25°C. The culture pH is suitably 5 to 9, preferably around 7 to 8. Culture may be either shaking culture or static culture, and bacterial cells can be obtained in 5 to 15 days, but static culture produces a higher amount of SBS. Extraction is then performed using an organic solvent such as methanol, ethanol, acetone, ethyl acetate, or chloroform.
精製は、順相及び逆相シリカゲル、逆相ODS。Purification was performed using normal phase and reversed phase silica gel, and reversed phase ODS.
セルロース等の吸着クロマトグラフィー、ゲルろ適法、
各種溶媒に対する溶解度の差を利用する方法等の一般的
な分離精製法を用いることができる。Adsorption chromatography of cellulose etc., gel filtration method,
General separation and purification methods such as methods that utilize differences in solubility in various solvents can be used.
以上のようにして得られた新規物質SBSは、次の理化
学的性質を有する。The novel substance SBS obtained as described above has the following physical and chemical properties.
1、 外観:白色粉末
2、 元素分析:C73,06% H11,85%3
、 分子量(FABマススペクトルによる)=4、 分
子式: C,5H,60゜
5、 比旋光度: 〔α〕20=+5.4°(c=1.
0、メタノール)
6、 紫外部吸収スペトクル(メタノール中);第1図
に示すように208nmに極
大吸収を示す。すなわち、第1図
7゜
8゜
9゜
は本物質を0.25 mg/−の濃度でメタノール中に
溶解させた場合の
紫外部吸収スペクトルを吸光度
(縦軸)と波長(nm、横軸)との
関係で示す図である。1. Appearance: White powder 2. Elemental analysis: C73.06% H11.85%3
, Molecular weight (according to FAB mass spectrum) = 4, Molecular formula: C, 5H, 60° 5, Specific optical rotation: [α] 20 = +5.4° (c = 1.
0, methanol) 6. Ultraviolet absorption spectrum (in methanol): As shown in Figure 1, maximum absorption is shown at 208 nm. That is, Figure 1 7゜8゜9゜ shows the ultraviolet absorption spectrum when this substance is dissolved in methanol at a concentration of 0.25 mg/-, and the absorbance (vertical axis) and wavelength (nm, horizontal axis). FIG.
赤外部吸収スペトクル(KBr錠):第2図に示すよう
に、3400.2990.
2960.2920.1380.
1180.945 cm−’に吸収を示す。すなわち第
2図は、本物質の
KBr錠の赤外部吸収スペクトルを
透過率(%、縦軸)と波数(cm−’
横軸)との関係で示す図である。Infrared absorption spectrum (KBr tablet): As shown in Figure 2, 3400.2990. 2960.2920.1380. It exhibits an absorption at 1180.945 cm-'. That is, FIG. 2 is a diagram showing the infrared absorption spectrum of the KBr tablet of the present substance in terms of the relationship between transmittance (%, vertical axis) and wave number (cm-', horizontal axis).
呈色反応:ニンヒドリン反応は陰性、フェノール硫酸反
応では糖の呈色性を
示さず。ヨウ素反応及び過マンガ
ン酸カリウム脱色反応では陽性。Color reaction: Ninhydrin reaction was negative, and phenol-sulfuric acid reaction showed no sugar coloration. Positive for iodine reaction and potassium permanganate decolorization reaction.
溶解性:メタノール、アセトン、クロロホルム、酢酸エ
チルに可溶、水、ヘ
キサンに難溶
10、酸性、中性、塩基性の区別:中性上記理化学的性
質に一致する既知物質は報告されていないので、SBS
は新規物質であると決定した。Solubility: Soluble in methanol, acetone, chloroform, and ethyl acetate, slightly soluble in water and hexane10, Distinction between acidic, neutral, and basic: Neutral No known substances that match the above physical and chemical properties have been reported. ,SBS
was determined to be a new substance.
次に本発明の新規物質SBSの生理活性を実験例により
示す。Next, the physiological activity of SBS, a novel substance of the present invention, will be illustrated by experimental examples.
実験例1 血小板凝集抑制作用
血小板凝集しゃく起物質として最終濃度5μg / m
l−のコラーゲンを用いた。日本内色種ウサギ血小板(
4X I O5/μfl) 0.2rnj7に、最終濃
度1〜50μg/mf!の新規物質SBSを添加し、そ
の30秒後にコラーゲンを添加して血小板の凝集を観察
した。その結果、以下の第1表に示す通り、新規物質S
BSは、明らかな血小板凝集抑制作用を有していた。Experimental Example 1 Platelet aggregation inhibitory effect: Final concentration of platelet aggregation stimulant: 5 μg/m
l-collagen was used. Japanese domestic colored rabbit platelets (
4X IO5/μfl) 0.2rnj7, final concentration 1-50μg/mf! 30 seconds later, collagen was added and platelet aggregation was observed. As a result, as shown in Table 1 below, the new substance S
BS had a clear platelet aggregation inhibitory effect.
第 1 表
SBS
1.0
10.0
3.0
18.6
実験例2 抗発ガンプロモーター作用発力゛ンプロモ
ーターテレ才シジンB−4(Teleocidin B
−4)が誘導するニブシュタインパール(Bpstei
n−Barr)ウィルスの早期抗原全抑制する効果をラ
ジ(Raji)細胞を用いたイン ビトロ(in vi
tro)の系で試験した。Table 1 SBS 1.0 10.0 3.0 18.6 Experimental Example 2 Anti-cancer promoter action potent promoter teleocidin B-4
-4) induced by Nibstein-Pearl (Bpstei)
The effect of completely suppressing early antigens of N-Barr virus was investigated in vitro using Raji cells.
tro) system.
ラジ細胞(5X 10 ’/rnl)を、20ng/m
fテレオシジンB−4、ジメチルスルホキシド5μm及
び3mMn−酪酸を含む培地で48時間培養し、早期抗
原を誘導した細胞を間接免疫蛍光法により検出した。同
様にして、新規物質SBSを最終濃度2μg/ml添加
したものと比較したところ、無添加に比べ早期抗原を誘
導した細胞数は、40%に抑えられた。この結果、新規
物質SBSに抗発ガンプロモーター作用があることが明
らかとなった。Raji cells (5X 10'/rnl) at 20ng/m
The cells were cultured for 48 hours in a medium containing f-teleosidin B-4, 5 μM dimethyl sulfoxide, and 3 mM n-butyric acid, and cells that induced early antigens were detected by indirect immunofluorescence. Similarly, when a new substance, SBS, was added at a final concentration of 2 μg/ml, the number of cells that induced early antigens was suppressed to 40% compared to when no addition was made. As a result, it was revealed that the new substance SBS has an anti-cancer promoter effect.
実験例3 急性毒性試験
ICRマウスに本発明の新規物質を経口投与した。10
00 mg/kg投与において毒性はg、v eられな
かった。Experimental Example 3 Acute toxicity test The novel substance of the present invention was orally administered to ICR mice. 10
No toxicity was observed at 00 mg/kg administration.
以上、本発明の物質は、以上の実験例に示した通り、血
小板凝集抑制作用、抗発ガンプロモーター作用を示し、
抗血栓剤、抗発ガン剤等として有用である。As shown in the above experimental examples, the substance of the present invention exhibits platelet aggregation inhibitory activity and anti-carcinogenic promoter activity,
It is useful as an antithrombotic agent, an anticarcinogenic agent, etc.
また、本物質は、リンパ球のコンカナバリンAによる幼
若化反応を抑制し、抗アレルギー剤としても有用である
。In addition, this substance suppresses the rejuvenation reaction of lymphocytes caused by concanavalin A, and is useful as an antiallergic agent.
次に、実施例を挙げて本発明を更に具体的に説胡するが
、本発明は以下の実施例の範囲に限定されるものではな
い。Next, the present invention will be explained in more detail with reference to examples, but the present invention is not limited to the scope of the following examples.
実施例1
「やまびこはんしめじ■」の子実体1.5kgを凍結乾
燥し、粉砕機で微粉末とした。酢酸エチル31を加えか
くはんしながら3時間抽出し、抽出物5.4gを得た。Example 1 1.5 kg of the fruiting body of "Yamabikohan Shimeji ■" was freeze-dried and made into a fine powder using a pulverizer. Ethyl acetate 31 was added and extracted for 3 hours with stirring to obtain 5.4 g of extract.
この抽出物を少量のクロロホルムに溶かし、75gのシ
リカゲル60(メルク社製)を充てんしクロロホルムで
洗浄したカラムに付した。11のクロロホルムで洗浄後
、クロロホルム−メタノール(4:1.V/V)溶液で
溶出し、溶出物1.1gを得た。この溶出物を分取用逆
相高速液体クロマトグラフィー〔カラム:カプセルパッ
クC86,φ10X250 mm、資生堂製 移動相:
メタノール−水(4: 1.V/V):]に付し、第3
図のクロマトパターンを得た。すなわち、第3図は逆相
高速液体クロマトグラフィーのクロマトパターンを示す
図であり、縦軸は吸光度(210nm)横軸は時間(分
)を示す。This extract was dissolved in a small amount of chloroform and applied to a column filled with 75 g of silica gel 60 (manufactured by Merck & Co., Ltd.) and washed with chloroform. After washing with 11 chloroform, elution was performed with a chloroform-methanol (4:1.V/V) solution to obtain 1.1 g of eluate. This eluate was subjected to preparative reverse phase high performance liquid chromatography [Column: Capsule Pack C86, φ10 x 250 mm, manufactured by Shiseido Mobile phase:
Methanol-water (4: 1.V/V):
The chromatographic pattern shown in the figure was obtained. That is, FIG. 3 is a diagram showing a chromatographic pattern of reversed phase high performance liquid chromatography, where the vertical axis shows absorbance (210 nm) and the horizontal axis shows time (minutes).
第3図のそれぞれの両分を分取し、A:18■、B:3
9■、C:44■、D:38■、E:56■、F :
61mg、G : 48 mg及びSBS:106■を
得た。Separate both portions of Figure 3, A: 18■, B: 3
9■, C: 44■, D: 38■, E: 56■, F:
61 mg, G: 48 mg and SBS: 106 ■ were obtained.
実施例2
リオフイラム ウルマリウムしul−8(FERM
BP−1416)株の斜面培地より100−の種培地(
グルコース2%、酵母エキス0.3%、ペプトン0.5
%、KH,PO,の0.1%、Mg5O1・7H20の
0.05%)を入れた500艷用三角フラスコに接種し
、25℃で14日間振とう培養して種培養液を得た。こ
の種培養液200dを、10Aの生産培地(種培地と同
組成)を入れた30f容ジャーファーメンタ−に接種し
、25℃、6日間通気かくはん培!(通気量101!/
分、かくはん20 Orpm )を行った。フィルター
プレスで集菌し、湿菌体830gを得た。この菌体を凍
結乾燥後、実施例1と同様の操作により、5B349■
を得た。Example 2 Lyophyllum ulmarium ul-8 (FERM
100- seed medium (
Glucose 2%, yeast extract 0.3%, peptone 0.5
%, 0.1% of KH, PO, and 0.05% of Mg5O1.7H20) and cultured with shaking at 25°C for 14 days to obtain a seed culture. 200 d of this seed culture solution was inoculated into a 30 f capacity jar fermenter containing 10 A production medium (same composition as the seed medium), and cultured at 25°C for 6 days with aeration. (Amount of ventilation 101!/
20 min). Bacteria were collected using a filter press to obtain 830 g of wet microbial cells. After freeze-drying this bacterial cell, 5B349■
I got it.
実施例3
実施例1で得た各面分の血小板凝集抑制作用及び抗発ガ
ンプロモーター作用を調べたところ、第2表の結果を得
た。血小板凝集抑制作用は、凝集剤としてコラーゲンを
用いたイン ビトロ系で検定し、抗発ガンプロモーター
作用は、発ガンプロモーターによるエブシュタインルウ
イルス活性化の抑制で検定した。Example 3 The platelet aggregation inhibitory effect and anti-carcinogenic promoter effect of each plate obtained in Example 1 were investigated, and the results shown in Table 2 were obtained. The platelet aggregation inhibitory effect was assayed in an in vitro system using collagen as an aggregating agent, and the anti-carcinogenic promoter activity was assayed by inhibiting Ebstein Le virus activation by an oncogenic promoter.
バー
第 2
表
B ++
++C++ 十+
D +++++
E 十
+十F 十十 干
C+ +SBS
++++ ++++(表中、十は活性の強
さを表し、その強さは++++>+++>十十>十 の
順である。また、−は活性がないことを示す)
〔発明の効果〕
本発明のSBSは、食用菌りオフィラム ウルマリウム
等によって生産される新規物質であり、血小板凝集抑制
作用及び抗発ガンプロモーター作用を有することから、
機能性食品素材等として有用である。Bar No. 2 Table B ++
++C++ 10+ D ++++++ E 10
+10F 10 Dried C+ +SBS
++++ ++++ (In the table, 10 represents the strength of activity, and the strength is in the order of ++++>+++>10>10. In addition, - indicates no activity) [Effects of the invention] The present invention SBS is a new substance produced by the edible fungus Rophyllum ulmarium and has anti-platelet aggregation and anti-carcinogenic promoter effects.
It is useful as a functional food material, etc.
第1図は新規物質SBSの紫外部吸収スペクトルを示す
図、第2図は同物質の光外部吸収スペクトル(KBr錠
)を示す図、第3図は、同物質の逆相高速液体クロマト
グラフィーの結果を示す図である。Figure 1 shows the ultraviolet absorption spectrum of the new substance SBS, Figure 2 shows the optical external absorption spectrum (KBr tablet) of the same substance, and Figure 3 shows the reversed phase high performance liquid chromatography of the same substance. It is a figure showing a result.
Claims (1)
0、2960、2920、 1380、1180、945cm^−^1 呈色反応:ニンヒドリン反応陰性、フェノール硫酸反応
陰性、ヨウ素反応陽性、 過マンガン酸カリウム脱色反応陽性 2、リオフイラム属に属する新規物質SBS生産菌の培
養物又は該生産菌の子実体より、請求項1記載の新規物
質SBSを採取することを特徴とする新規物質SBSの
製造方法。[Claims] 1. A new substance SBS having the following physical and chemical properties. Elemental analysis: C73.06% H11.85% Molecular weight: 738 (by FAB-mass spectrum) Molecular formula: C_4_5H_6_6O_7 Ultraviolet absorption spectrum (in methanol): Maximum absorption at 208 nm Infrared absorption spectrum (KBr tablet): 3400, 299
0, 2960, 2920, 1380, 1180, 945 cm^-^1 Color reaction: Negative ninhydrin reaction, negative phenol sulfuric acid reaction, positive iodine reaction, positive potassium permanganate decolorization reaction 2, new substance SBS-producing bacteria belonging to the genus Liophyllum A method for producing the novel substance SBS, which comprises collecting the novel substance SBS according to claim 1 from a culture of or a fruiting body of the producing bacterium.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21810490A JP2860963B2 (en) | 1990-08-21 | 1990-08-21 | New substance SBS and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21810490A JP2860963B2 (en) | 1990-08-21 | 1990-08-21 | New substance SBS and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04104795A true JPH04104795A (en) | 1992-04-07 |
JP2860963B2 JP2860963B2 (en) | 1999-02-24 |
Family
ID=16714698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP21810490A Expired - Lifetime JP2860963B2 (en) | 1990-08-21 | 1990-08-21 | New substance SBS and method for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2860963B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018095A1 (en) * | 2005-08-09 | 2007-02-15 | Takara Bio Inc. | Method of producing extract derived from hypsizigus marmoreus |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1754473A4 (en) * | 2004-05-31 | 2010-03-03 | Takara Bio Inc | Antitumor agent |
-
1990
- 1990-08-21 JP JP21810490A patent/JP2860963B2/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018095A1 (en) * | 2005-08-09 | 2007-02-15 | Takara Bio Inc. | Method of producing extract derived from hypsizigus marmoreus |
JP5084505B2 (en) * | 2005-08-09 | 2012-11-28 | タカラバイオ株式会社 | Method for producing extract from Bunashimeji |
Also Published As
Publication number | Publication date |
---|---|
JP2860963B2 (en) | 1999-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0733647B1 (en) | Polysaccharides and preparation thereof | |
US4010258A (en) | Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus | |
JPH01228480A (en) | Production of extract of cultured mycelia of edible basidiomycete | |
EP0459367B1 (en) | Method for preparing an antitumor dextran | |
KR870001930B1 (en) | Preparation method of polysaccharides,ron | |
US4687764A (en) | Hypotriglyceridemically active polysaccharides | |
US6120772A (en) | Oral drugs for treating AIDS patients | |
EP0491114B1 (en) | A process for preparing new non-covalent polysaccharide-protein associations having pharmacological activity | |
JPH04104795A (en) | Novel substance sbs and production thereof | |
JPH01193265A (en) | Novel antitumor antibiotic sf2587 substance and its production | |
JPS58318B2 (en) | Method for producing anticancer substances | |
JPH01246288A (en) | Tan-1030a and its derivative, production and use thereof | |
JPS63209579A (en) | Cultivation of cordyceps sinensis sacc. | |
JP2546239B2 (en) | Novel substance ovalicin | |
US5641485A (en) | Caledothricins used in the treatment mycotic diseases | |
JP2000159807A (en) | Fraction of lentinula hypha extract and its use | |
JPH07506332A (en) | Phosphate esters of heterocyclic compounds as medicines | |
JPH0368041B2 (en) | ||
JPH01121302A (en) | Mucilaginous polysaccharide substance and production thereof | |
JPH06287142A (en) | Anti-hiv agent | |
JPS596890A (en) | Antitumor substance 5117 and preparation thereof | |
JPH0571232B2 (en) | ||
JPS59172466A (en) | Antibiotic substance, pyrrolidinomycin | |
JPH0156074B2 (en) | ||
JPS5922517B2 (en) | Method for producing antitumor polysaccharide C↓-45 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071211 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081211 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081211 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091211 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101211 Year of fee payment: 12 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101211 Year of fee payment: 12 |